- Home
- OABI vs CRBU Comparison
OABI vs CRBU Comparison
Compare OABI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- CRBU
- Stock Information
- Founded
- OABI 2012
- CRBU 2011
- Country
- OABI United States
- CRBU United States
- Employees
- OABI N/A
- CRBU N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- OABI Health Care
- CRBU Health Care
- Exchange
- OABI Nasdaq
- CRBU Nasdaq
- Market Cap
- OABI 239.0M
- CRBU 203.9M
- IPO Year
- OABI N/A
- CRBU 2021
- Fundamental
- Price
- OABI $1.58
- CRBU $2.15
- Analyst Decision
- OABI Strong Buy
- CRBU Strong Buy
- Analyst Count
- OABI 3
- CRBU 3
- Target Price
- OABI $6.67
- CRBU $9.33
- AVG Volume (30 Days)
- OABI 544.6K
- CRBU 4.7M
- Earning Date
- OABI 11-04-2025
- CRBU 11-12-2025
- Dividend Yield
- OABI N/A
- CRBU N/A
- EPS Growth
- OABI N/A
- CRBU N/A
- EPS
- OABI N/A
- CRBU N/A
- Revenue
- OABI $21,094,000.00
- CRBU $9,121,000.00
- Revenue This Year
- OABI N/A
- CRBU $8.06
- Revenue Next Year
- OABI $48.89
- CRBU N/A
- P/E Ratio
- OABI N/A
- CRBU N/A
- Revenue Growth
- OABI 3.36
- CRBU N/A
- 52 Week Low
- OABI $1.22
- CRBU $0.66
- 52 Week High
- OABI $4.61
- CRBU $3.54
- Technical
- Relative Strength Index (RSI)
- OABI 49.87
- CRBU 42.89
- Support Level
- OABI $1.33
- CRBU $1.93
- Resistance Level
- OABI $1.64
- CRBU $2.26
- Average True Range (ATR)
- OABI 0.09
- CRBU 0.26
- MACD
- OABI 0.01
- CRBU -0.04
- Stochastic Oscillator
- OABI 55.92
- CRBU 11.93
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.